Literature DB >> 1730817

All products of proglucagon are elevated in plasma from uremic patients.

C Orskov1, J Andreasen, J J Holst.   

Abstract

We measured and characterized the proglucagon (PG) products in plasma obtained from nine uremic patients and six control subjects in the fasting state. The concentrations of PG products measured by direct RIAs were significantly higher in the uremic patients than in the normal subjects; the concentration of total glucagon immunoreactivity in plasma was 209 +/- 20 vs. 70 +/- 11 pmol/L, the glucagon-like peptide-1 immunoreactivity was 154 +/- 33 vs. 41 +/- 13 pmol/L, and the concentration of pancreatic-type glucagon immunoreactivity was 53 +/- 6 vs. 30 +/- 7 pmol/L. By chromatography, the predominating PG products in both uremic and normal plasma were shown to be glicentin [corresponding to PG-(1-69)] and the major PG fragment [presumably corresponding to PG-(72-158)]. In addition, glucagon-like peptide-1 [presumably corresponding to PG-(72-107) amide] was a major product in uremic plasma. Our results suggest that the kidneys play an important role in the removal from plasma of these products of PG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730817     DOI: 10.1210/jcem.74.2.1730817

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.

Authors:  Priscila C Sala; Raquel S Torrinhas; Steven B Heymsfield; Dan L Waitzberg
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

2.  Inhibition of human gastric lipase secretion by glucagon-like peptide-1.

Authors:  M Wøjdemann; A Wettergren; B Sternby; J J Holst; S Larsen; J F Rehfeld; O Olsen
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 3.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Authors:  G-R Martin; P-L Beck; D-L Sigalet
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

4.  Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients.

Authors:  Anna Masajtis-Zagajewska; Ilona Kurnatowska; Małgorzata Wajdlich; Marta Jagodzińska; Michał Nowicki
Journal:  Int Urol Nephrol       Date:  2013-05-14       Impact factor: 2.370

5.  Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects.

Authors:  P A Velasquez-Mieyer; P A Cowan; G E Umpierrez; R H Lustig; A K Cashion; G A Burghen
Journal:  Int J Obes Relat Metab Disord       Date:  2003-11

Review 6.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

Review 7.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

8.  Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans.

Authors:  Katja Piotrowski; Melanie Becker; Julia Zugwurst; Ingeborg Biller-Friedmann; Gerald Spoettl; Martin Greif; Alexander W Leber; Alexander Becker; Rüdiger P Laubender; Corinna Lebherz; Burkhard Goeke; Nikolaus Marx; Klaus G Parhofer; Michael Lehrke
Journal:  Cardiovasc Diabetol       Date:  2013-08-16       Impact factor: 9.951

9.  Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans.

Authors:  Justyna Modrzynska; Christine F Klein; Kasper Iversen; Henning Bundgaard; Bolette Hartmann; Maike Mose; Nikolaj Rittig; Niels Møller; Jens J Holst; Nicolai J Wewer Albrechtsen
Journal:  Endocr Connect       Date:  2021-02       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.